Anti-VEGF Receptor 2 Polyclonal Antibody for WB, ELISA - P35968

Core Product Specifications and Parameters

Biological Background: VEGF Receptor 2 Function and Localization

• VEGF Receptor 2 (VEGFR2), also known as KDR, FLK-1, or CD309, is a transmembrane tyrosine kinase receptor that serves as the primary mediator of VEGFA-driven angiogenesis and vascular permeability. It also binds VEGFC and VEGFD, playing essential roles in vascular development and embryonic hematopoiesis.
• As a key regulator of endothelial cell biology, VEGFR2 promotes proliferation, survival, migration, and differentiation of endothelial cells, and is critical for the reorganization of the actin cytoskeleton.
• VEGFR2 activation triggers multiple downstream signaling cascades, including the MAPK/ERK pathway, AKT1 pathway, and PLCG1-mediated calcium mobilization. It also phosphorylates PIK3R1, NOS3, SRC, and PTK2/FAK1, linking it to nitric oxide production and focal adhesion dynamics.
• The human KDR gene encodes several isoforms. Isoform 1 is the full-length receptor, while isoforms lacking the transmembrane domain (isoforms 2 and 3) act as soluble decoy receptors, negatively regulating lymphangiogenesis by sequestering VEGFA and VEGFC.
• VEGFR2 is predominantly localized to the cell membrane, but also detected at cell junctions, in the cytoplasm, nucleus, endoplasmic reticulum, early endosomes, and can be secreted, reflecting its dynamic trafficking and signaling roles.
• Widely expressed, it is detected at the protein level in cornea, and is heavily post-translationally modified by phosphorylation, glycosylation, and ubiquitination, as indicated by UniProt keywords.

Experimental Guidance and Technical Tips

• The immunogen is a synthetic peptide spanning amino acids 1150-1250 within the C-terminal intracellular domain. This region is distant from known major phosphorylation sites and should be accessible in both denatured (WB) and native (ELISA) conditions. However, verify epitope availability in your specific sample system.
• The predicted molecular weight of human VEGFR2 is 151.5 kDa (UniProt) / 152 kDa (supplier), with potential glycosylation causing migration at higher apparent masses. In WB, run sufficiently high-percentage gels and include appropriate molecular weight markers to resolve the mature receptor.
• This antibody demonstrates cross-reactivity with mouse and rat VEGFR2, making it suitable for multi-species studies. Confirm target specificity in your model organism by knockdown or knockout controls if possible.
• For ELISA, consider using the antibody as both capture and detection in a sandwich format if you pair it with a non-competing monoclonal or polyclonal raised against a different epitope. Standard checkerboard titrations are advisable.
• Because this is a polyclonal antibody, minor lot-to-lot variation may occur. Include internal reference controls for reproducibility across experiments and validate any new lot before large-scale use.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, core labs, and research institutes with streamlined access to validated IVD raw materials. This anti-VEGFR2 rabbit polyclonal antibody exemplifies our portfolio for angiogenesis and cancer research, offering reliable performance for WB and ELISA. In addition to primary antibodies, we supply matched antibody pairs, monoclonal alternatives, bulk ancillary reagents, and can source rare-target raw materials to support your entire assay development pipeline, from concept to clinic.